Browsing by Author "Wedemeyer, Heiner"
Now showing items 1-12 of 12
-
96 weeks of pegylated-Interferon- alpha-2? plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study
Wedemeyer, Heiner; Yurdaydin, Cihan; Ernst, Stefanie; Caruntu, Florin A.; Curescu, Manuela G.; Yalcin, Kendal; Akarca, Ulus S. (Wiley-Blackwell, 2013)[Abstract Not Available] -
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
Keskin, Onur; Wedemeyer, Heiner; Tuzun, Ali; Zachou, Kalliopi; Deda, Xheni; Dalekos, George N.; Heidrich, Benjamin (Elsevier Science Inc, 2015)BACKGROUND & AIMS: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international ... -
BASELINE ALT LEVELS BUT NOT HDV-RNA LEVELS ARE ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT OF DELTA HEPATITIS: DATA FROM THE HIDIT-1 TRIAL
Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; Erhardi, Annette; Cakaloglu, Yilmaz; Yalcin, Kendal; Gurel, Selim (John Wiley & Sons Inc, 2008)[Abstract Not Available] -
Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study
Hardtke, Svenja; Wedemeyer, Heiner; Caruntu, Florin Alexandru; Curescu, Manuela; Kendal, Yalcin; Akarca, Ulus; Yurdcu, Esra (Elsevier, 2019)[Abstract Not Available] -
Implications of HBsAg, HBcAg and HDAg Immunohistochemistry in Course and Treatment of Chronic Delta Hepatitis (CDH)
Kabacam, Gokhan; Wedemeyer, Heiner; Heidrich, Benjamin; Yalcin, Kendal; Onder, Fatih Oguz; Dienes, Hans P.; Manns, Michael P. (Wiley-Blackwell, 2012)[Abstract Not Available] -
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus adevofir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adevofir dipivoxil for the treatment of chronic delta hepatitis: The hep-net/international delta hepatitis intervention trial (HID-IT)
Yurdaydin, Cihan; Wedemeyer, Heiner; Dalekos, George; Erhardt, Alexander; Cakaloglu, Ya; Degertekin, Ha; Gurel, Sa. (John Wiley & Sons Inc, 2006)[Abstract Not Available] -
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
Wedemeyer, Heiner; Yurdaydin, Cihan; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G.; Yalcin, Kendal; Akarca, Ulus S. (Elsevier Sci Ltd, 2019)Background Hepatitis D is the most severe form of chronic viral hepatitis. Treatment guidelines recommend 1 year of peginterferon alfa, which is effective in 25-30% of patients only. Whether prolonged therapy with peginterferon ... -
Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia
Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; Erhardt, Alexander; Drebber, Ulrike; Cakaloglu, Ya; Degertekin, Ha (John Wiley & Sons Inc, 2006)[Abstract Not Available] -
Pegylated-Interferon-a-2a plus Tenofovir or Placebo for the treatment of hepatitis delta: First results of the HIDIT-2 study
Yurdaydin, Cihan; Wedemeyer, Heiner; Caruntu, Florin A.; Curescu, Manuela G.; Yalcin, Kendal; Akarca, Ulus S.; Gurel, Selim (Wiley-Blackwell, 2012)[Abstract Not Available] -
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study
Bremer, Birgit; Anastasiou, Olympia E.; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G.; Yalçın, Kendal; Akarca, Ulus S.; Gürel, Selim; Zeuzem, Stefan; Erhardt, Andreas; Luth, Stefan; Papatheodoridis, George, V.; Radu, Monica; Idilman, Ramazan; Manns, Michael P.; Cornberg, Markus; Yurdaydın, Cihan; Wedemeyer, Heiner (Wiley, 2020)The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with ... -
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta
Kabaçam, Gökhan; Wedemeyer, Heiner; Savaş, Berna; Dalekos, George; Tabak, Fehmi; İdilman, Ramazan; Erhardt, Andreas; Yalçın, Kendal; Bozdayı, Mithat A.; Bozkaya, Hakan; Manns, Michael; Dienes, Hans; Yurdaydın, Cihan; Keskin, Onur (WILEY-BLACKWELL, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2014)Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ... -
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta
Wranke, Anika; Hardtke, Svenja; Heidrich, Benjamin; Dalekos, George; Yalçın, Kendal; Tabak, Fehmi; Gürel, Selim; Çakaloglu, Yılmaz; Akarca, Ulus S.; Lammert, Frank; Haeussinger, Dieter; Mueller, Tobias; Woebse, Michael; Manns, Michael P.; İdilman, Ramazan; Cornberg, Markus; Wedemeyer, Heiner; Yurdaydın, Cihan (Wiley, 2020)Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFN alpha-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this ...
